INCY · 10-Q · 2026Q3 · Full report

Medicare Drug Price Negotiation

INCYTE CORP · 2026-10-29 · Importance 29 · Surprise 24

The Inflation Reduction Act created a Medicare drug price negotiation selection process that could apply to ruxolitinib phosphate. Incyte states that the ORPHAN Cures Act extended the period before ruxolitinib phosphate becomes eligible for selection. The filing gives no dollar estimate or specific revised eligibility date for this effect.

Key facts

• The ORPHAN Cures Act extended the period before ruxolitinib phosphate becomes eligible for selection for Medicare drug price negotiation because JAKAFI has orphan drug designations for MF, PV and GVHD. source